Entera Bio (ENTX)

• Market cap: $77.3M
• 1 day: -2.78%
• 5 days: -2.33%
• 1 month: 35.48%
• 3 months: 3.45%
• 6 months: 1.94%
• Year to date: 220.66%
• 1 year: 195.77%
• 5 years: 6.06%
• 10 years: -66.56%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Employees: 20

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

13% more funds holding

Funds holding: 15 [Q2] → 17 (+2) [Q3]

4% more capital invested

Capital invested by funds: $9.75M [Q2] → $10.1M (+$367K) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

0.12% less ownership

Funds ownership: 14.78% [Q2] → 14.65% (-0.12%) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $10 376% upside
• Avg. target: $10 376% upside
• High target: $10 376% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 39% 1-year accuracy 121 / 308 met price target

376% upside $10

Buy Reiterated

11 Nov 2024